# Fluvoxamine for Adults With Mild to Moderate COVID-19

> **NCT04711863** · PHASE2 · SUSPENDED · sponsor: **Asan Medical Center** · enrollment: 400 (estimated)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- Coronavirus Infection
- Mild to Moderate COVID-19

## Interventions

- **DRUG:** Fluvoxamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04711863
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-01-16
- **Primary completion:** 2021-05-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 400 (ESTIMATED)
- **Why stopped:** Closure of main community treatment center
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711863, "Fluvoxamine for Adults With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04711863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*